Activation of the JAK/STAT pathway in vascular smooth muscle by serotonin

Amy K.L. Banes, Seán M. Shaw, Amany Tawfik, Bela P. Patel, Safia Ogbi, David Fulton, Mario B. Marrero

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Serotonin (5-hydroxytryptamine, 5-HT) is a vasoconstrictor and mitogen whose levels are elevated in diabetes. Previous studies have shown the presence of 5-HT2A, 5-HT2B, and 5-HT1B receptors in vascular smooth muscle cells (VSMCs). There are currently no data regarding 5-HT2B and 5-HT1B receptor activation of the JAK/STAT pathway in VSMCs and resultant potential alterations in 5-HT signaling in diabetes. Therefore, we tested the hypothesis that 5-HT differentially activates the JAK/ STAT pathway in VSMCs under conditions of normal (5 mM) and high (25 mM) glucose. Treatment of rat VSMCs with 5-HT (10-6 M) resulted in time-dependent activation (∼2-fold) of JAK2, JAK1, and STAT1, but not STAT3 (maximal at 5 min, returned to baseline by 30 min). The 5-HT2B receptor agonist BW723C86 and the 5-HT1B receptor agonist CGS12066A (10-9-10-5 M, 5-min stimulation) did not activate the JAK/STAT pathway. Treatment with the 5-HT2A receptor antagonist ketanserin (10 nM) inhibited JAK2 activation by 5-HT. Treatment of streptozotocin-induced diabetic rats with ketanserin (5 mg·kg -1·day-1) reduced activation of JAK2 and STAT1 but not STAT3 in endothelium-denuded thoracic aorta in vivo. 5-HT (10-6 M) treatment resulted in increased cell proliferation and increased DNA synthesis, which were inhibited by the JAK2 inhibitor AG490. Further studies with apocynin, diphenyleneiodonium chloride, catalase, and virally transfected superoxide dismutase had no effect at either glucose concentration on activation of the JAK/STAT pathway by 5-HT. Therefore, we conclude that 5-HT activates JAK2, JAK1, and STAT1 via the 5-HT2A receptors in a reactive oxygen species-independent manner under both normal and high glucose conditions.

Original languageEnglish (US)
Pages (from-to)C805-C812
JournalAmerican Journal of Physiology - Cell Physiology
Volume288
Issue number4 57-4
DOIs
StatePublished - Apr 1 2005

Fingerprint

Vascular Smooth Muscle
Muscle
Serotonin
Chemical activation
Receptor, Serotonin, 5-HT1B
Smooth Muscle Myocytes
Receptor, Serotonin, 5-HT2A
Ketanserin
Medical problems
Glucose
Rats
Receptor, Serotonin, 5-HT2B
Serotonin 5-HT2 Receptor Agonists
Serotonin 5-HT1 Receptor Agonists
Serotonin 5-HT2 Receptor Antagonists
Cell proliferation
Vasoconstrictor Agents
Streptozocin
Thoracic Aorta
Mitogens

Keywords

  • 5-hydroxytryptamine
  • Reactive oxygen species

ASJC Scopus subject areas

  • Physiology
  • Cell Biology

Cite this

Activation of the JAK/STAT pathway in vascular smooth muscle by serotonin. / Banes, Amy K.L.; Shaw, Seán M.; Tawfik, Amany; Patel, Bela P.; Ogbi, Safia; Fulton, David; Marrero, Mario B.

In: American Journal of Physiology - Cell Physiology, Vol. 288, No. 4 57-4, 01.04.2005, p. C805-C812.

Research output: Contribution to journalArticle

Banes, Amy K.L. ; Shaw, Seán M. ; Tawfik, Amany ; Patel, Bela P. ; Ogbi, Safia ; Fulton, David ; Marrero, Mario B. / Activation of the JAK/STAT pathway in vascular smooth muscle by serotonin. In: American Journal of Physiology - Cell Physiology. 2005 ; Vol. 288, No. 4 57-4. pp. C805-C812.
@article{1a84d744c57747a6a51bdbda41a5f429,
title = "Activation of the JAK/STAT pathway in vascular smooth muscle by serotonin",
abstract = "Serotonin (5-hydroxytryptamine, 5-HT) is a vasoconstrictor and mitogen whose levels are elevated in diabetes. Previous studies have shown the presence of 5-HT2A, 5-HT2B, and 5-HT1B receptors in vascular smooth muscle cells (VSMCs). There are currently no data regarding 5-HT2B and 5-HT1B receptor activation of the JAK/STAT pathway in VSMCs and resultant potential alterations in 5-HT signaling in diabetes. Therefore, we tested the hypothesis that 5-HT differentially activates the JAK/ STAT pathway in VSMCs under conditions of normal (5 mM) and high (25 mM) glucose. Treatment of rat VSMCs with 5-HT (10-6 M) resulted in time-dependent activation (∼2-fold) of JAK2, JAK1, and STAT1, but not STAT3 (maximal at 5 min, returned to baseline by 30 min). The 5-HT2B receptor agonist BW723C86 and the 5-HT1B receptor agonist CGS12066A (10-9-10-5 M, 5-min stimulation) did not activate the JAK/STAT pathway. Treatment with the 5-HT2A receptor antagonist ketanserin (10 nM) inhibited JAK2 activation by 5-HT. Treatment of streptozotocin-induced diabetic rats with ketanserin (5 mg·kg -1·day-1) reduced activation of JAK2 and STAT1 but not STAT3 in endothelium-denuded thoracic aorta in vivo. 5-HT (10-6 M) treatment resulted in increased cell proliferation and increased DNA synthesis, which were inhibited by the JAK2 inhibitor AG490. Further studies with apocynin, diphenyleneiodonium chloride, catalase, and virally transfected superoxide dismutase had no effect at either glucose concentration on activation of the JAK/STAT pathway by 5-HT. Therefore, we conclude that 5-HT activates JAK2, JAK1, and STAT1 via the 5-HT2A receptors in a reactive oxygen species-independent manner under both normal and high glucose conditions.",
keywords = "5-hydroxytryptamine, Reactive oxygen species",
author = "Banes, {Amy K.L.} and Shaw, {Se{\'a}n M.} and Amany Tawfik and Patel, {Bela P.} and Safia Ogbi and David Fulton and Marrero, {Mario B.}",
year = "2005",
month = "4",
day = "1",
doi = "10.1152/ajpcell.00385.2004",
language = "English (US)",
volume = "288",
pages = "C805--C812",
journal = "American Journal of Physiology - Heart and Circulatory Physiology",
issn = "0363-6135",
publisher = "American Physiological Society",
number = "4 57-4",

}

TY - JOUR

T1 - Activation of the JAK/STAT pathway in vascular smooth muscle by serotonin

AU - Banes, Amy K.L.

AU - Shaw, Seán M.

AU - Tawfik, Amany

AU - Patel, Bela P.

AU - Ogbi, Safia

AU - Fulton, David

AU - Marrero, Mario B.

PY - 2005/4/1

Y1 - 2005/4/1

N2 - Serotonin (5-hydroxytryptamine, 5-HT) is a vasoconstrictor and mitogen whose levels are elevated in diabetes. Previous studies have shown the presence of 5-HT2A, 5-HT2B, and 5-HT1B receptors in vascular smooth muscle cells (VSMCs). There are currently no data regarding 5-HT2B and 5-HT1B receptor activation of the JAK/STAT pathway in VSMCs and resultant potential alterations in 5-HT signaling in diabetes. Therefore, we tested the hypothesis that 5-HT differentially activates the JAK/ STAT pathway in VSMCs under conditions of normal (5 mM) and high (25 mM) glucose. Treatment of rat VSMCs with 5-HT (10-6 M) resulted in time-dependent activation (∼2-fold) of JAK2, JAK1, and STAT1, but not STAT3 (maximal at 5 min, returned to baseline by 30 min). The 5-HT2B receptor agonist BW723C86 and the 5-HT1B receptor agonist CGS12066A (10-9-10-5 M, 5-min stimulation) did not activate the JAK/STAT pathway. Treatment with the 5-HT2A receptor antagonist ketanserin (10 nM) inhibited JAK2 activation by 5-HT. Treatment of streptozotocin-induced diabetic rats with ketanserin (5 mg·kg -1·day-1) reduced activation of JAK2 and STAT1 but not STAT3 in endothelium-denuded thoracic aorta in vivo. 5-HT (10-6 M) treatment resulted in increased cell proliferation and increased DNA synthesis, which were inhibited by the JAK2 inhibitor AG490. Further studies with apocynin, diphenyleneiodonium chloride, catalase, and virally transfected superoxide dismutase had no effect at either glucose concentration on activation of the JAK/STAT pathway by 5-HT. Therefore, we conclude that 5-HT activates JAK2, JAK1, and STAT1 via the 5-HT2A receptors in a reactive oxygen species-independent manner under both normal and high glucose conditions.

AB - Serotonin (5-hydroxytryptamine, 5-HT) is a vasoconstrictor and mitogen whose levels are elevated in diabetes. Previous studies have shown the presence of 5-HT2A, 5-HT2B, and 5-HT1B receptors in vascular smooth muscle cells (VSMCs). There are currently no data regarding 5-HT2B and 5-HT1B receptor activation of the JAK/STAT pathway in VSMCs and resultant potential alterations in 5-HT signaling in diabetes. Therefore, we tested the hypothesis that 5-HT differentially activates the JAK/ STAT pathway in VSMCs under conditions of normal (5 mM) and high (25 mM) glucose. Treatment of rat VSMCs with 5-HT (10-6 M) resulted in time-dependent activation (∼2-fold) of JAK2, JAK1, and STAT1, but not STAT3 (maximal at 5 min, returned to baseline by 30 min). The 5-HT2B receptor agonist BW723C86 and the 5-HT1B receptor agonist CGS12066A (10-9-10-5 M, 5-min stimulation) did not activate the JAK/STAT pathway. Treatment with the 5-HT2A receptor antagonist ketanserin (10 nM) inhibited JAK2 activation by 5-HT. Treatment of streptozotocin-induced diabetic rats with ketanserin (5 mg·kg -1·day-1) reduced activation of JAK2 and STAT1 but not STAT3 in endothelium-denuded thoracic aorta in vivo. 5-HT (10-6 M) treatment resulted in increased cell proliferation and increased DNA synthesis, which were inhibited by the JAK2 inhibitor AG490. Further studies with apocynin, diphenyleneiodonium chloride, catalase, and virally transfected superoxide dismutase had no effect at either glucose concentration on activation of the JAK/STAT pathway by 5-HT. Therefore, we conclude that 5-HT activates JAK2, JAK1, and STAT1 via the 5-HT2A receptors in a reactive oxygen species-independent manner under both normal and high glucose conditions.

KW - 5-hydroxytryptamine

KW - Reactive oxygen species

UR - http://www.scopus.com/inward/record.url?scp=15444366204&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15444366204&partnerID=8YFLogxK

U2 - 10.1152/ajpcell.00385.2004

DO - 10.1152/ajpcell.00385.2004

M3 - Article

C2 - 15601754

AN - SCOPUS:15444366204

VL - 288

SP - C805-C812

JO - American Journal of Physiology - Heart and Circulatory Physiology

JF - American Journal of Physiology - Heart and Circulatory Physiology

SN - 0363-6135

IS - 4 57-4

ER -